Safety and Efficacy of B-Cell Depletion with Rituximab for the Treatment of Systemic Sclerosis–associated Pulmonary Arterial Hypertension: A Multicenter, Double-Blind, Randomized, Placebo-controlled Trial
- 15 July 2021
- journal article
- research article
- Published by American Thoracic Society in American Journal of Respiratory and Critical Care Medicine
- Vol. 204 (2), 209-221
- https://doi.org/10.1164/rccm.202009-3481oc
Abstract
Rationale: Systemic sclerosis (SSc)-pulmonary arterial hypertension (PAH) is one of the most prevalent and deadly forms of PAH. B cells may contribute to SSc pathogenesis. Objectives: We investigated the safety and efficacy of B-cell depletion for SSc-PAH. Methods: In an NIH-sponsored, multicenter, double-blinded, randomized, placebo-controlled, proof-of-concept trial, 57 patients with SSc-PAH on stable-dose standard medical therapy received two infusions of 1,000 mg rituximab or placebo administered 2 weeks apart. The primary outcome measure was the change in 6-minute-walk distance (6MWD) at 24 weeks. Secondary endpoints included safety and invasive hemodynamics. We applied a machine learning approach to predict drug responsiveness. Measurements and Main Results: We randomized 57 subjects from 2010 to 2018. In the primary analysis, using data through Week 24, the adjusted mean change in 6MWD at 24 weeks favored the treatment arm but did not reach statistical significance (23.6 +/- 11.1mvs. 0.5 +/- 9.7 m; P = 0.12). Although a negative study, when data through Week 48 were also considered, the estimated change in 6MWD at Week 24 was 25.5 +/- 8.8 m for rituximab and 0.4 +/- 7.4 m for placebo (P = 0.03). Rituximab treatment appeared to be safe and well tolerated. Low levels of RF (rheumatoid factor), IL-12, and IL-17 were sensitive and specific as favorable predictors of a rituximab response as measured by an improved 6MWD (receiver operating characteristic area under the curve, 0.88-0.95). Conclusions: B-cell depletion therapy is a potentially effective and safe adjuvant treatment for SSc-PAH. Future studies in these patients can confirm whether the identified biomarkers predict rituximab responsiveness.Keywords
This publication has 68 references indexed in Scilit:
- B-cell subpopulations in humans and their differential susceptibility to depletion with anti-CD20 monoclonal antibodiesArthritis Research & Therapy, 2013
- A rheumatoid factor paradox: inhibition of rituximab effector functionArthritis Research & Therapy, 2013
- Limited Systemic Sclerosis Patients with Pulmonary Arterial Hypertension Show Biomarkers of Inflammation and Vascular InjuryPLOS ONE, 2010
- Increased IL-12 inhibits B cells' differentiation to germinal center cells and promotes differentiation to short-lived plasmablastsThe Journal of Experimental Medicine, 2008
- Rituximab treatment of pulmonary arterial hypertension associated with systemic lupus erythematosus: a case reportLupus, 2008
- Molecular Subsets in the Gene Expression Signatures of Scleroderma SkinPLOS ONE, 2008
- Peripheral blood B lymphocytes derived from patients with idiopathic pulmonary arterial hypertension express a different RNA pattern compared with healthy controls: a cross sectional studyRespiratory Research, 2008
- Drug Insight: the mechanism of action of rituximab in autoimmune disease—the immune complex decoy hypothesisNature Clinical Practice Rheumatology, 2007
- Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritisArthritis & Rheumatism, 2006
- Autoimmunity and pulmonary hypertension: a perspectiveEuropean Respiratory Journal, 2005